随机化COVID-19疫苗接种推广可直接提供真实世界证据
本文提出一种可快速嵌入的COVID-19疫苗接种推广策略,通过在推广中利用随机化,在大规模人群中直接获得疫苗安全性及可能疗效的真实世界证据,弥补传统研究难以获取的知识,并为未来疫苗及更多干预提供借鉴。
要点
- 随机化推广接种可在大规模人群中直接生成疫苗安全性真实世界证据。
- 该策略可快速嵌入接种推广,缓解疫情下获益与风险证据不足的担忧。
- 此方法可为COVID-19及未来疫苗和其他干预提供重要证据。
核心结论
- 在COVID-19疫苗接种推广中嵌入随机化,可大规模直接产生疫苗安全性及可能疗效的真实世界证据。
临床怎么用
- 接种推广设计时可考虑嵌入随机化,以同步积累大规模安全性及可能疗效的真实世界证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccines are vital to control the Coronavirus disease 2019 (COVID-19) pandemic, but the pressure to quickly move from research to implementation in the context of a pandemic crisis raises concerns about benefits and harms, vaccine acceptance and fair access. Here we present a strategy for the COVID-19 vaccination rollout which can be rapidly embedded and would offer direct real-world evidence of vaccines on a large scale to generate otherwise unobtainable knowledge on the safety and perhaps efficacy of COVID-19 vaccines. Such strategic rollouts leveraging randomization can provide important evidence, for COVID-19 and in future occasions, for vaccines and beyond.
引用
- Hemkens LG, Goodman SN. Randomized COVID-19 vaccination rollout can offer direct real-world evidence. J Clin Epidemiol. 2021. PMID: 34048910. doi:10.1016/j.jclinepi.2021.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。